NYSE:BCR C.R. Bard (BCR) Stock Price, News & Analysis → Don’t expose yourself to stocks during the week (From DTI) (Ad) Free BCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$331.24▼$331.2450-Day Range N/A52-Week Range$222.42▼$337.73VolumeN/AAverage Volume679,456 shsMarket CapitalizationN/AP/E Ratio21.91Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get C.R. Bard alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About C.R. Bard Stock (NYSE:BCR)C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.Read More Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. BCR Stock News HeadlinesApril 13, 2024 | sports.yahoo.comRockies relief pitcher Daniel Bard needs elbow surgery, will miss rest of seasonApril 13, 2024 | msn.comDaniel Bard Won't Return In 2024April 18, 2024 | Darwin (Ad)Your Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)April 12, 2024 | msn.comRockies reliever Daniel Bard to undergo season-ending flexor tendon surgeryApril 12, 2024 | msn.comRockies RHP Daniel Bard to have season-ending elbow surgeryApril 12, 2024 | msn.comRockies RHP Daniel Bard needs elbow surgery, will miss rest of seasonApril 10, 2024 | msn.comDealer Gavin Brown Donates His Archive to Bard College's Curatorial Studies ProgramApril 10, 2024 | msn.comBard Prison Initiative gets $4.5M in federal fundingApril 18, 2024 | Darwin (Ad)Your Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)April 2, 2024 | msn.comInside a completely free program at Bard MicrocollegeMarch 29, 2024 | msn.comDaniel Bard Begins Season On Injured ListFebruary 20, 2024 | msn.comWhat is Google Bard? Everything you need to know about the ChatGPT rivalFebruary 14, 2024 | msn.comDaniel Bard will be sidelined for five to seven weeks after suffering a tear in his meniscus.February 13, 2024 | msn.comRockies reliever Daniel Bard will have surgery to repair a torn meniscus in left kneeFebruary 8, 2024 | msn.comGoogle is rebranding its Bard AI service as Gemini. Here's what it means.February 8, 2024 | msn.comGoogle rebrands Bard to Gemini, now available for the first time in mobileFebruary 8, 2024 | msn.comGoogle rebrands Bard to Gemini – and Geminis everywhere are offendedFebruary 7, 2024 | msn.comBard is becoming Gemini and getting a paid versionFebruary 7, 2024 | msn.comHow to use Google Bard: Everything you should knowFebruary 5, 2024 | msn.comGoogle Bard to be rebranded as Gemini – reportsFebruary 5, 2024 | msn.comGoogle Bard's rebranding to Gemini might just be around the cornerFebruary 4, 2024 | msn.comBard image creator is hereFebruary 2, 2024 | msn.comFilm, health care, and Bard early college: New high schools coming to Brooklyn and QueensFebruary 1, 2024 | msn.comGoogle Bard adds image generationFebruary 1, 2024 | msn.comBard generates photos now, finallyJanuary 31, 2024 | msn.comGoogle confirms you’ll need to pay for Bard Advanced — here’s what it can doJanuary 31, 2024 | msn.comGoogle's Bard Advanced is getting a subscription paywall soonSee More Headlines Receive BCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C.R. Bard and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/25/2017Today4/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryHealth Care Equipment Current SymbolNYSE:BCR CUSIP06738310 CIK9892 Webwww.crbard.com Phone+1-908-2778000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio21.91 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesTimothy M. Ring (Age 59)Chairman of the Board, Chief Executive Officer John H. Weiland (Age 61)President, Vice Chairman of the Board, Chief Operating Officer James C. Beasley (Age 53)Group President Timothy P. Collins (Age 56)Group President John P. Groetelaars (Age 50)Group President Christopher S. Holland (Age 50)Chief Financial Officer, Senior Vice President Samrat S. Khichi (Age 49)Senior Vice President, General Counsel, Secretary John A. DeFord Ph.D. (Age 55)Senior Vice President - Science, Technology and Clinical Affairs Frank Lupisella Jr. (Age 56)Vice President, Controller Betty D. Larson (Age 41)Vice President - Human Resources More Executives BCR Stock Analysis - Frequently Asked Questions How were C.R. Bard's earnings last quarter? C.R. Bard Inc (NYSE:BCR) released its quarterly earnings results on Wednesday, October, 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping analysts' consensus estimates of $2.96 by $0.06. The medical instruments supplier had revenue of $989.80 million for the quarter, compared to analysts' expectations of $990.64 million. The business's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.64 earnings per share. Is C.R. Bard a good dividend stock? C.R. Bard (NYSE:BCR) pays an annual dividend of $0.78 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 5.16%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for BCR. What other stocks do shareholders of C.R. Bard own? Based on aggregate information from My MarketBeat watchlists, some companies that other C.R. Bard investors own include Abbott Laboratories (ABT), Becton, Dickinson and Company (BDX), Medtronic (MDT), Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), AbbVie (ABBV), Baxter International (BAX), Boston Scientific (BSX), Aflac (AFL) and Stryker (SYK). This page (NYSE:BCR) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe “Perfect Storm” for GoldGold Safe ExchangeUrgent alert: open this for a huge profit potentialTimothy SykesTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressYour Money is Not SafeAmerican AlternativeForget Nvidia, buy this A.I. Stock NowInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C.R. Bard Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.